English Archives - Sidra Medicine

Baker Alzidaneen

Dr. Baker A. Alzidaneen is a Neurosurgery Specialist at Sidra Medicine, where he has been practicing since 2022. He provides advanced neurosurgical care for children with complex neurological conditions, with a particular focus on pediatric brain tumors, hydrocephalus, spinal disorders, and congenital anomalies of the nervous system.

Dr. Alzidaneen has expertise in skull base surgery using navigation-assisted technology, minimally invasive spine surgery, and the management of spinal tumors. His clinical interests also include brain injury pathology, functional neurosurgery, and pediatric neuroscience. Prior to joining Sidra Medicine, he worked as a Neurosurgery Specialist at King Hussein Medical City in Jordan.

He holds the Jordanian Board of Neurosurgery and the Arab Spine Diploma and is a member of the North American Spine Society. Dr. Alzidaneen is licensed to practice in Qatar, Jordan, and Abu Dhabi and is committed to delivering evidence-based care for children with complex neurosurgical conditions.

16 June, 2026

Sidra Medicine Publishes Groundbreaking Report on Novel Treatment for Rare Pediatric Obesity Case

A case report by Sidra Medicine, a member of Qatar Foundation, has been published in Frontiers in Endocrinology detailing the successful treatment of severe acquired hypothalamic obesity (aHO) in a young child.

10 June, 2026

Sidra Medicine Achieves ANCC Pathway to Excellence Designation with Distinction

Sidra Medicine, a member of Qatar Foundation, has become the first hospital in Qatar to achieve the prestigious American Nurses Credentialing Center (ANCC) Pathway to Excellence designation with distinction.

2 June, 2026

Sidra Medicine and Zulal Wellness Resort by Chiva-Som Sign MoU to Elevate Wellness Programs

Sidra Medicine and Zulal Wellness Resort by Chiva-Som, members of Qatar Foundation, officially signed a Memorandum of Understanding (MoU) to collaborate on the development of integrated wellness and preventive health programs.

19 May, 2026

Rapid International Coordination by Sidra Medicine Ensures Uninterrupted Specialized Care for Baby

A baby successfully received a custom 3D-printed cranial remodeling helmet, following a specialized procedure at Sidra Medicine and a rapid coordinated effort by multiple teams across borders.

13 May, 2026

Sidra Medicine Advanced Imaging Core Recognized as ZEISS labs@location Reference Customer

Sidra Medicine, a member of Qatar Foundation, has been formally designated as a ZEISS labs@location Reference Customer through its Advanced Imaging Core (AIC).

5 May, 2026

Sidra Medicine Advances Pediatric Sports Care with Growth-Sparing Surgical Techniques

Sidra Medicine, a member of Qatar Foundation, is advancing orthopedic care in Qatar with the introduction of a specialized pediatric orthopedic sports medicine service. The latest offering from the Orthopedics Department, delivers growth-sparing surgical techniques, tailored for children and young adults.

28 April, 2026

Sidra Medicine to Expand Pediatric Therapy Capabilities with New Sensory Integration Gym

Sidra Medicine, is developing a new Sensory Integration Gym as part of its continued expansion of specialized pediatric rehabilitation services. The gym will provide an advanced therapeutic environment for children with neurodevelopmental, behavioral, and sensory processing challenges.

27 April, 2026

Msheireb Museums and Sidra Medicine Champion Neurodiversity in Second Science Café Session

Msheireb Museums and Sidra Medicine hosted the second session of the 2026 Science Café series on Monday, which convened leading experts who discussed neurodevelopmental conditions from the perspective of science, technology, ability and achievement under the theme “Different Abilities, Shared Futures: Disability and Success.”

21 April, 2026

Sidra Medicine introduces Qatar’s first advanced gene-editing therapy for sickle cell disease and thalassemia

Sidra Medicine, a member of Qatar Foundation, has been qualified by Vertex Pharmaceuticals as one of a of a limited number of hospitals in the world, to administer Casgevy, a groundbreaking, one-time CRISPR/Cas9-based gene therapy treatment.